BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst (Nasdaq: BCRX) will report fourth quarter 2025 financial results on Thursday, February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst (Nasdaq: BCRX) will report fourth quarter 2025 financial results on Thursday, February 26, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a corporate update.
Live domestic and international dial‑in numbers are provided, and a webcast replay will be available in the investors section of the company website.
Details
News Market Reaction – BCRX
On Feb 5, the day this news came out, BCRX closed 2.80% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Earnings release date
- February 26, 2026
- Scheduled Q4 2025 financial results announcement
- Conference call time
- 8:30 a.m. ET
- Time of Q4 2025 results call and webcast
- Domestic dial-in
- 1-844-481-2942
- U.S. access number for earnings conference call
- International dial-in
- 1-412-317-1866
- International access number for earnings conference call
Historical Context
-
Closed Astria Therapeutics acquisition, adding Phase 3 HAE asset and leadership.
-
Reported 2025 ORLADEYO net revenue of $601M, beating prior guidance range.
-
Granted 18,300 RSUs to new hire under Nasdaq inducement equity plan.
-
Announced presentation slot at 44th Annual J.P. Morgan Healthcare Conference.
-
Received FDA approval for ORLADEYO oral pellets for HAE patients aged 2–<12.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on Thursday, February 26, 2026.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.